• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Healthcare·6543.TWO
Share

Perfect Medical Industry Co., Ltd. Stocks

NT$ 17.3Last Updated 19.10.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Considerable

Recommendation

Hold

Market Cap

NT$ 33.90M

NT$ 17.3
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Decent dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Perfect Medical Industry Co., Ltd. is a Taiwanese enterprise specializing in the manufacturing and global distribution of a diverse range of health and medical supplies. Their extensive product portfolio encompasses critical medical consumables, including specialized tubing and needle sets for procedures like hemodialysis and A.V. fistula, as well as various huber and winged needle sets, blood transfusion and safety infusion sets, safety extension sets, I.V. locks, disposable syringes, and medical face masks. These offerings are marketed under the 'PF' brand, reaching a broad international customer base across Asia, Africa, Europe, and South America. Established in 1989, the company maintains its headquarters in Changhua, Taiwan.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITD

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

21.10.2026 01:11

SpaceX's earnings were more than double market expectations

21.10.2026 00:45

The Wells Fargo indicator has issued a buy signal for the first time in nearly 1.5 years

20.10.2026 23:27

AI giants are pushing for data center savings. Who stands to lose?

20.10.2026 22:32

DeepSeek open-sources tool to help cut AI operating costs

20.10.2026 21:47

‘Roller coaster’: What Wall Street expects from SpaceX third-quarter earnings

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026